Entering text into the input field will update the search result below

Cyclerion reports Q2 results; updates data readouts in next 12 months

  • Cyclerion Therapeutics (CYCN) Q2 results: Revenues: $1.6M.
  • Net loss: ($32.3M) (-8.4%); loss/share: ($1.18) (-8.3%); Quick Assets: $141M.
  • Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019.
  • Phase 2 study of olinciguat in sickle cell disease on track for data readout in mid-2020.
  • Phase 1 study of IW-6463, central nervous system penetrant sGC stimulator is on track for data readout in Q4 2019.
  • Cyclerion will host a webcast event focused on praliciguat cardiometabolic programs on September 17 in New York City ahead of anticipated clinical results.
  • Previously: Cyclerion Therapeutics EPS misses by $0.34 (Aug. 12)

Recommended For You

More Trending News

About CYCN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CYCN--
Cyclerion Therapeutics, Inc.